AffiliationChristie NHS Foundation Trust, Manchester, UK
MetadataShow full item record
AbstractThe use of IVIG to treat a wide variety of immune-driven diseases has grown rapidly, although the mechanism of action is not completely understood. Increasing demand for IVIG coupled with concerns regarding potential transmissible agents has led to worldwide supply shortages. National agencies have therefore produced guidelines for its use, with the latest England and Wales guideline being published in 2011. Due to the rarity of the rheumatic diseases, the evidence for IVIG use has been shown to be lacking in some areas and promising in others. Conditions in which IVIG has been shown to have benefit include ITP, Guillain-Barré syndrome and chronic inflammatory demyelinating polyneuropathy occurring in the context of rheumatic disease, as well as in SLE, idiopathic inflammatory myopathies and ANCA-associated vasculitides. This review looks at current IVIG use and is designed to be an aid for rheumatologists when considering the use of IVIG in clinical practice.
CitationIndications for IVIG in rheumatic diseases. 2014: Rheumatology
- Intravenous immunoglobulin therapy in rheumatic diseases.
- Authors: Bayry J, Negi VS, Kaveri SV
- Issue date: 2011 Jun
- Intravenous Immunoglobulin in Pediatric Rheumatology: When to Use It and What Is the Evidence.
- Authors: Rodriguez MM, Wagner-Weiner L
- Issue date: 2017 Jan 1
- [Intravenous immunoglobulin (IVIG)].
- Authors: Hara M
- Issue date: 2009 Mar
- Intravenous immunoglobulin treatment of neurological autoimmune diseases.
- Authors: Stangel M, Hartung HP, Marx P, Gold R
- Issue date: 1998 Jan 8
- Intravenous immunoglobulin in paediatric neurology: safety, adherence to guidelines, and long-term outcome.
- Authors: Nosadini M, Mohammad SS, Suppiej A, Sartori S, Dale RC, IVIG in Neurology Study Group
- Issue date: 2016 Nov